Document:

<PAGE>

--------------------------------------------------------------------------------
Loyola University Chicago                            Exclusive License Agreement
Bio-Bridge Science Corporation                                       Page 1 of 5
--------------------------------------------------------------------------------

                           EXCLUSIVE LICENSE AGREEMENT

WHEREAS Liang Qiao and Wei Shi, of 6526 Maxwell Drive, Woodridge, Illinois 60517
and 3436 South Union Avenue, #1F, Chicago,  Illinois 60616,  respectively,  have
invented  certain  technology  pertaining to  PAPILLOMAVIRUS  PSEUDOVIRIONS AS A
GENETIC VECTOR AND VACCINE ("the Technology"),

WHEREAS Liang Qiao and Wei Shi have  assigned the entirety of their  interest to
the  Technology in all  countries to Loyola  University  Chicago,  of 2160 South
First Avenue, Maywood, Illinois 60153 (hereinafter referred to as "Loyola"),

WHEREAS  Loyola is desirous of developing the Technology in the United States of
America, Japan, China and

WHEREAS  Bio-Bridge  Science  Corporation of Scotia Center,  4th Floor, P.O. Box
2804,  George Town,  Grand Caymen,  Caymen Islands  (hereinafter  referred to as
"Bio-Bridge ") desires to obtain an exclusive  license to the Technology  within
the United States of America,  Japan and People's  Republic of China  (including
mainland China, Taiwan, Hong Kong and Macau);

NOW THEREFORE, for good and valuable mutual consideration,  the receipt of which
Bio-Bridge and Loyola hereby acknowledge, the following is hereby agreed between
Loyola and Bio-Bridge:

1.   Loyola grants to Bio-Bridge an exclusive  license to the Technology  within
     the United States of America,  Japan, and People's Republic of China, which
     license includes the following:

     A.   Bio-Bridge  shall have the exclusive  right to make,  have made,  use,
          sell,  and offer to sell the  Technology  within the United  States of
          America, Japan and People's Republic of China.

     B.   Bio-Bridge shall have the exclusive right to file patent  applications
          for any aspect of the Technology,  at Bio-Bridge's  expense but in the
          name of Dr.  Liang Qiao and Dr. Wei Shi,  within the United  States of
          America, Japan and People's Republic of China.

<PAGE>

--------------------------------------------------------------------------------
Loyola University Chicago                            Exclusive License Agreement
Bio-Bridge Science Corporation                                       Page 2 of 5
--------------------------------------------------------------------------------

     C.   Bio-Bridge shall enjoy, as exclusive licensee,  the full and exclusive
          right to any patent that might issue in the United  States of America,
          Japan, People's Republic of China on any patent application concerning
          the Technology, but any such patents shall be owned by the University.
          Bio-Bridge  shall be  responsible  for all  expenses  associated  with
          maintaining any such patents in force.

     D.   Bio-Bridge shall have the right to grant  nonexclusive  sublicenses to
          use the  technology  to its  customers  within  the  United  States of
          America,  Japan and  People's  Republic  of China on any such terms as
          Bio-Bridge desires.

     E.   Bio-Bridge shall have the right to grant  nonexclusive  sublicenses to
          make any aspect of the  Technology to its suppliers  within the United
          States of America, Japan, People's Republic of China on any such terms
          as Bio-Bridge desires.

     F.   Bio-Bridge may grant  exclusive  sublicenses to the Technology  within
          the United  States of America,  Japan,  People's  Republic of China on
          such terms as it desires, after first giving written notice to Loyola,
          which may veto the sublicense or any term thereof,  within thirty (30)
          days of receiving such notice.

     G.   Bio-Bridge  shall  have  the  right  to  enforce  its  rights  to  the
          Technology in any way it deems appropriate,  including filing suit for
          infringement of any patent granted  thereon,  within the United States
          of  America,  Japan,  People's  Republic of China,  provided  that any
          enforcement  shall  be  at  Bio-Bridge's  expense  and  provided  that
          Bio-Bridge  notify  Loyola within thirty (30) days of any act taken to
          enforce its rights in the United States of America, Japan and People's
          Republic of China.

2.   Loyola shall continue to own the entire worldwide rights to the Technology,
     including any  improvements  thereon,  including any  improvements  made by
     Bio-Bridge.

3.   Bio-Bridge  shall  notify  Loyola  within  thirty  (30) days of any  patent
     applications it might file, as well as of all events during the prosecution
     of such  patents,  including  the  issuance of any patents  granted on such
     application.

<PAGE>

--------------------------------------------------------------------------------
Loyola University Chicago                            Exclusive License Agreement
Bio-Bridge Science Corporation                                       Page 3 of 5
--------------------------------------------------------------------------------

4.   Bio-Bridge Science  Corporation shall reimburse  Loyola's  expenditures and
     legal fees  ($3,000.00) in granting the exclusive  license stated herein to
     Bio-Bridge Science  Corporation in each of the  above-mentioned  countries.
     Any such reimbursement shall be payable in U.S. Dollars and shall be due to
     Loyola  within 30 days of Loyola's  issuance to Bio-Bridge of a request for
     reimbursement identifying the fees.

5.   Bio-Bridge shall pay to Loyola 4% (four percent) net profit for all uses of
     the  Technology  within the United  States of America,  Japan and  People's
     Republic of China,  including  the uses of any of  Bio-Bridge  sublicenses.
     Such payments are payable in U.S. Dollars and shall be due to Loyola within
     30 days of June 1 and December 1 of each calendar year, or immediately upon
     termination of this Agreement.

6.   Bio-Bridge  shall  make  annual  reports  to  Loyola  indicating  all  uses
     (including  the  uses  of  any  of  Bio-Bridge  sublicenses  and  all  fees
     Bio-Bridge  receives from the granting of any sublicenses of the Technology
     within the United States of America, Japan and People's Republic of China),
     including a statement of the net profit  realized  from each such use. Such
     statements  shall be supplied to Loyola within 45 days of January 1 of each
     year.

7.   This Agreement will continue to exist perpetually or for the maximum period
     of time  permitted  by law,  unless  terminated,  and it shall inure to the
     benefit of and bind all successors-in-interest of the parties hereto.

8.   This Agreement shall not be modified except by written instrument  executed
     by both Bio-Bridge and Loyola.

9.   Bio-Bridge  may  terminate  this  Agreement in total by  providing  written
     notice  specifying the date upon which the agreement is to be terminated to
     the other party no earlier than 45 days and no later than 30 days preceding
     the date upon which the Agreement is to be terminated. Loyola may terminate
     this  Agreement  under  such a  condition:  Dr.  Liang  Qiao  will  provide
     Bio-Bridge  with a  specific  product  (vaccine)  which has been  tested in
     animal models and clinical trials for safety and effectiveness.  Bio-Bridge
     will apply for the government  permit of its  production in America,  Japan
     and People's  Republic of China. Once the permits are granted to Bio-Bridge
     by the U.S., Japan and China  governments,  Bio-Bridge shall pay $50,000.00
     to  Loyola  within  thirty  days.  Five  years  after  U.S.,  Japan,  China
     governments  have granted the permit for its production,  if Bio-Bridge has
     not made any effort in marketing  this  product,  then Loyola may terminate
     this Agreement.

<PAGE>

--------------------------------------------------------------------------------
Loyola University Chicago                            Exclusive License Agreement
Bio-Bridge Science Corporation                                       Page 4 of 5
--------------------------------------------------------------------------------

10.  Upon termination of this Agreement,  all sublicenses  granted by Bio-Bridge
     Science  Corporation within the United States of America,  Japan,  People's
     Republic  shall  terminate,  and  Loyola  shall not be liable in any way to
     Bio-Bridge Science Corporation due to termination of any such sublicense.

11.  Upon termination of this Agreement,  Bio-Bridge shall immediately supply to
     Loyola a report  such as  specified  in  paragraph  6 for the  period  from
     January 1 through  the date of  termination  and shall  immediately  pay to
     Loyola all  royalties or other fees due to Loyola up to and  including  the
     date of termination.

12.  Any excuse or  variance of  performance  on the part of any party shall not
     act as a modification of this Agreement or in any way diminish the right of
     each  party  to  demand  the  other  party's  full  performance  under  the
     Agreement.

13.  This Agreement shall be interpreted in accordance with the law of the State
     of  Illinois,  and it shall be  enforceable  in the  courts of that  State.
     Neither party shall object to submitting to the  jurisdiction of the courts
     of that State with respect to any matter relating to this Agreement.

14.  The terms set forth in this  instrument  constitute  the  entire  Agreement
     between the parties with respect to the Technology, and it is the intent of
     the  parties  to  substitute  the  terms  set  forth  herein  for any prior
     understanding  pertaining to the Technology  that may have existed  between
     them at any time,  and the effect of this  Agreement is to  extinguish  any
     such  understanding that contradicts or in any way goes beyond the terms of
     the Agreement as set forth herein.

15.  Should any  portion  of this  Agreement  be deemed by a court of  competent
     jurisdiction  to be  unenforceable  for any reason,  the  remainder  of the
     Agreement shall remain in force.

<PAGE>

--------------------------------------------------------------------------------
Loyola University Chicago                            Exclusive License Agreement
Bio-Bridge Science Corporation                                       Page 5 of 5
--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties hereby signify their assent to the terms of this
Agreement by the  signatures  of their  representatives,  each of whom is hereby
acknowledged  to have  authority to enter into  contracts and otherwise bind his
respective party:

--------------------------------------------------------------------------------
For Loyola:                                For Bio-Bridge Science Corporation

Date: 4/22/02                              Date: 2002.4.15

     /s/ John A. Robinson                       /s/ Yu Mingjin
     --------------------------------           -------------------------------

     John A. Robinson, M.D.                     President
     Associate Dean of Research                 Bio-Bridge Science Corporation
     Professor of Medicine and Microbiology     Scotia Center,  4th Floor,
       and Immunology                           P.O. Box 2804, George Town,
     Loyola University of Chicago               Grand Caymen, Caymen Islands
     Maywood, IL 60153
     United States of America
--------------------------------------------------------------------------------<PAGE>
--------------------------------------------------------------------------------
Beijing Bio-Bridge Science Corporation           Exclusive Sub-License Agreement
Bio-Bridge Science Corporation                                       Page 1 of 3
--------------------------------------------------------------------------------

                         EXCLUSIVE SUB-LICENSE AGREEMENT

WHEREAS Liang Qiao and Wei Shi, of 6526 Maxwell Drive, Woodridge, Illinois 60517
and 3436 South Union Avenue, #1F, Chicago,  Illinois 60616,  respectively,  have
invented  certain  technology  pertaining to  PAPILLOMAVIRUS  PSEUDOVIRIONS AS A
GENETIC VECTOR AND VACCINE ("the Technology"),

WHEREAS Liang Qiao and Wei Shi have  assigned the entirety of their  interest to
the  Technology in all  countries to Loyola  University  Chicago,  of 2160 South
First Avenue, Maywood, Illinois 60153 (hereinafter referred to as "Loyola"),

WHEREAS Loyola has signed an exclusive license agreement with Bio-Bridge Science
Corporation  of Scotia  Center,  4th Floor,  P.O. Box 2804,  George Town,  Grand
Caymen,  Caymen Islands  (hereinafter  referred to as  "Bio-Bridge")  to use the
Technology in areas specified in the agreement.

WHEREAS  Bio-Bridge  herein  sub-licensed  the  Technology at no charge (with no
royalities)  to its  subsidiary,  Beijing  Bio-Beijing  Science  Corporation  of
Beijing,  Tianzhu  Export  Processing  Zone,  the  People's  Republic  of  China
(hereinafter  referred to as "Beijing Bio-Bridge ") to use the Technology within
China( Mainland China);

NOW THEREFORE, for good and valuable mutual consideration,  the receipt of which
Bio-Bridge and Beijing  Bio-Bridge hereby  acknowledge,  the following is hereby
agreed between Loyola and Bio-Bridge:

1.   Bio-Bridge  sub-licenses to Beijing  Bio-Bridge an exclusive license to the
     Technology  within  China ( Mainland  China),  which  license  includes the
     following:

     A.   Beijing  Bio-Bridge shall have the exclusive right to make, have made,
          use, sell, and offer to sell the Technology within Mainland China.

     B.   Beijing  Bio-Bridge  shall  have the  exclusive  right to file  patent
          applications for any aspect of the Technology, at Beijing Bio-Bridge's
          expense  but in the name of Dr.  Liang  Qiao and Dr.  Wei Shi,  within
          Mainland China.

     C.   Beijing  Bio-Bridge shall enjoy, as exclusive  licensee,  the full and
          exclusive  right to any patent that might  issue in Mainland  China on
          any patent application concerning the Technology, but any such patents
          shall be owned by Loyola.  Beijing Bio-Bridge shall be responsible for
          all expenses associated with maintaining any such patents in force.
<PAGE>
--------------------------------------------------------------------------------
Beijing Bio-Bridge Science Corporation           Exclusive Sub-License Agreement
Bio-Bridge Science Corporation                                       Page 2 of 3
--------------------------------------------------------------------------------

     D.   Beijing   Bio-Bridge  shall  have  the  right  to  grant  nonexclusive
          sublicenses  to use the  technology to its customers  within  Mainland
          China on any such terms as Beijing Bio-Bridge desires.

     E.   Beijing   Bio-Bridge  shall  have  the  right  to  grant  nonexclusive
          sublicenses  to make any  aspect of the  Technology  to its  suppliers
          within Mainland China on any such terms as Beijing Bio-Bridge desires.

     F.   Beijing  Bio-Bridge  shall have the right to enforce its rights to the
          Technology in any way it deems appropriate,  including filing suit for
          infringement  of any patent granted  thereon,  within  Mainland China,
          provided that any enforcement shall be at Beijing Bio-Bridge's expense
          and provided that Beijing  Bio-Bridge notify Bio-Bridge within fifteen
          (15) days of any act taken to enforce its rights in Mainland China.

2.   Beijing  Bio-Bridge shall notify Bio-Bridge within fifteen (15) days of any
     patent  applications  it might  file,  as well as of all events  during the
     prosecution of such patents,  including the issuance of any patents granted
     on such application.

3.   Beijing  Bio-Bridge  shall use the Technology at no charge ( no royal fees)
     within the agreement effective period.

4.   Beijing  Bio-Bridge shall make quarterly  reports to Bio-Bridge  indicating
     all uses (including the uses of any of Beijing  Bio-Bridge  sublicenses and
     all fees Beijing  Bio-Bridge  receives from the granting of any sublicenses
     of the  Technology  within  Mainland  China),  including a statement of the
     after-tax  profit  realized  from each such use. Such  statements  shall be
     supplied to Bio-Bridge within 30 days of January 1 of each year.

5.   This Agreement will continue to exist for ten ( 10 years) unless terminated
     by the force of laws,  and it shall  inure to the  benefit  of and bind all
     successors-in-interest of the parties hereto.

6.   This Agreement shall not be modified except by written instrument  executed
     by both Bio-Bridge and Beijing Bio-Bridge.

7.   Upon  termination of this  Agreement,  all  sublicenses  granted by Beijing
     Bio-Bridge Science  Corporation within Mainland China shall terminate,  and
     Bio-Bridge  shall not be liable in any way to  Beijing  Bio-Bridge  Science
     Corporation due to termination of any such sublicense.

<PAGE>
--------------------------------------------------------------------------------
Beijing Bio-Bridge Science Corporation           Exclusive Sub-License Agreement
Bio-Bridge Science Corporation                                       Page 3 of 3
--------------------------------------------------------------------------------

8.   Upon termination of this Agreement,  Beijing  Bio-Bridge shall  immediately
     supply to Loyola a report such as  specified  in paragraph 6 for the period
     from January 1 through the date of termination.

9.   Any excuse or  variance of  performance  on the part of any party shall not
     act as a modification of this Agreement or in any way diminish the right of
     each  party  to  demand  the  other  party's  full  performance  under  the
     Agreement.

10.  This  Agreement  shall be  interpreted  in  accordance  with the law of the
     Caymen  Islands,  and it shall  be  enforceable  in the  courts  of  Caymen
     Islands.  Neither party shall object to submitting to the  jurisdiction  of
     the courts of Caymen  Islands with  respect to any matter  relating to this
     Agreement.

11.  The terms set forth in this  instrument  constitute  the  entire  Agreement
     between the parties with respect to the Technology, and it is the intent of
     the  parties  to  substitute  the  terms  set  forth  herein  for any prior
     understanding  pertaining to the Technology  that may have existed  between
     them at any time,  and the effect of this  Agreement is to  extinguish  any
     such  understanding that contradicts or in any way goes beyond the terms of
     the Agreement as set forth herein.

12.  Should any  portion  of this  Agreement  be deemed by a court of  competent
     jurisdiction  to be  unenforceable  for any reason,  the  remainder  of the
     Agreement shall remain in force.

IN WITNESS WHEREOF, the parties hereby signify their assent to the terms of this
Agreement by the  signatures  of their  representatives,  each of whom is hereby
acknowledged  to have  authority to enter into  contracts and otherwise bind his
respective party:

--------------------------------------------------------------------------------
For Bio-Bridge Science Corporation    For Beijing Bio-Bridge Science Corporation

Date: 2002.6.17                       Date: 2002.6.20

/s/ Yu Mingjin                        /s/ Qiao Wenhui
----------------------------------    ------------------------------------------
President                             President
Bio-Bridge Science Corporation        Beijing Bio-Bridge Science Corporation
Scotia  Center,  4th Floor,           Beijing, PRC
P.O.  Box 2804,  George
Town, Grand Caymen, Caymen Islands
--------------------------------------------------------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]